Water → (R)-4-(2-(1-Ethyl-1H-pyrrol-2-yl)ethyl)-4-methyloxazolidin-2-one
反応式
[NH2:1][C@:2]([CH3:14])([CH2:5][CH2:6][C:7]1[N:8]([CH2:12][CH3:13])[CH:9]=[CH:10][CH:11]=1)[CH2:3][OH:4].[C:15](OC(OC(C)(C)C)=O)(OC(C)(C)C)=[O:16].C(N(CC)CC)C.O>C(Cl)Cl.CN(C)C1C=CN=CC=1.C(OCC)(=O)C>[CH3:14][C@@:2]1([CH2:5][CH2:6][C:7]2[N:8]([CH2:12][CH3:13])[CH:9]=[CH:10][CH:11]=2)[CH2:3][O:4][C:15](=[O:16])[NH:1]1参加物
反応物 4
生成物 1
試薬・触媒・溶媒 3
実験手順
The thus obtained (2R)-2-amino-2-methyl-4-(1-ethylpyrrol-2-yl)butan-1-ol ½ D-(−)-tartrate (55.5 mg, 0.160 mmol) was suspended in methylene chloride (1.6 mL) and di-t-butyl dicarbonate (0.17 g, 0.78 mmol), triethylamine (0.22 mL, 1.58 mmol) and 4-dimethylaminopyridine (3.0 mg, 0.025 mmol) were added thereto, followed by stirring of the mixture at room temperature for 20 minutes. Water and ethyl acetate were added thereto to separate it. The thus obtained organic phase was separated and dried over anhydrous sodium sulfate. The solvent was evaporated under reduced pressure and the residue was purified by silica gel chromatography (hexane:ethyl acetate, 1:1) to obtain (4R)-4-methyl-4-[2-(1-ethylpyrrol-2-yl)ethyl]-1,3-oxazolidin-2-one (18.0 mg, yield: 58%).
後処理
- customto separate it
- customThe thus obtained organic phase was separated
- dry with materialdried over anhydrous sodium sulfate
- customThe solvent was evaporated under reduced pressure
- customthe residue was purified by silica gel chromatography (hexane:ethyl acetate, 1:1)
出典と根拠
- ORDレコード
- ord-627443735c97443697898c2ee72e7ff2
- 出典データセット
- uspto-grants-2011_03
- 特許番号
- US07910617B2
反応ノート
読み込み中…